Published online before print June 3, 2005

This Article Full Text Full Text (PDF) All Versions of this Article: jlb.0604360v1 78/2/359    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brando, C. Articles by Santoli, D. Search for Related Content PubMed PubMed Citation Articles by Brando, C. Articles by Santoli, D.

(Journal of Leukocyte Biology. 2005;78:359-371.)
© 2005 by Society for Leukocyte Biology

Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104

Clara Brando^*,1, Sunil Mukhopadhyay^*,2, Eniko Kovacs^*, Rosa Medina^*,3, Pritesh Patel^*,4, Tracey L. Catina, Kerry S. Campbell^,5 and Daniela Santoli^*

^* The Wistar Institute, Philadelphia, Pennsylvania; and
Fox Chase Cancer Center, Philadelphia, Pennsylvania

⁵ Correspondence: Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111-2497. E-mail: kerry.campbell{at}fccc.edu

The major histocompatibility complex nonrestricted cytotoxic leukemic T cell line T acute lymphoblastic leukemia (TALL)-104 is being pursued as a therapeutic agent for cancer. However, the receptors and effector mechanisms responsible for its broad tumoricidal function remain undefined. Here, we examined the roles played by natural cytotoxicity receptors (NCR), killer cell immunoglobulin-like receptors, cytolytic granule components, and tumor necrosis factor (TNF) family members in tumor recognition and lysis by TALL-104 cells. The perforin-granzyme pathway, TNF-related apoptosis-inducing ligand (TRAIL), and Fas were each involved in the lysis of particular tumor targets by TALL-104. Furthermore, phorbol 12-myristate 13-acetate/ionomycin treatment induced surface expression of Fas-L and TRAIL. In addition, supernatants from CD3-stimulated TALL-104 cultures exhibited antiproliferative activity, which was blocked 50–90% by anti-TNF- monoclonal antibody (mAb). Although negative for the NCR natural killer (NK)p44, this cell line was found to express NKp46. An anti-NKp46 antibody strongly blocked TALL-104-mediated lysis of certain targets and directly induced cytokine production, granule release, and redirected lysis responses. Anti-NKG2D and anti-2B4 also stimulated redirected cytotoxicity by TALL-104. By contrast, anti-NKG2A mAb did not stain the cells or inhibit killing responses. Alternatively, KIR3DL2 was detected on TALL-104, and expression of its reported ligand, human leukocyte antigen (HLA)-A, on target cells provided protection from cytotoxicity. Thus, NKp46, NKG2D, and 2B4 are activating receptors, and KIR3DL2 is an inhibitory receptor on TALL-104. The data demonstrate the ability of TALL-104 cells to recognize a wide variety of tumors with NK cell receptors and kill them with a broad arsenal of cytolytic effector mechanisms, including cytolytic granules and TNF family ligands.

Key Words: cancer therapy • cytotoxic mechanisms • regulatory receptors

This article has been cited by other articles:

				E. L. Brincks, A. Katewa, T. A. Kucaba, T. S. Griffith, and K. L. Legge CD8 T Cells Utilize TRAIL to Control Influenza Virus Infection J. Immunol., October 1, 2008; 181(7): 4918 - 4925. [Abstract] [Full Text] [PDF]

				Y. Ganor, V. I. Teichberg, and M. Levite TCR Activation Eliminates Glutamate Receptor GluR3 from the Cell Surface of Normal Human T Cells, via an Autocrine/Paracrine Granzyme B-Mediated Proteolytic Cleavage J. Immunol., January 15, 2007; 178(2): 683 - 692. [Abstract] [Full Text] [PDF]